Cargando…

Biofilm of Helicobacter pylori: Life Cycle, Features, and Treatment Options

Helicobacter pylori is a gastric pathogen that infects nearly half of the global population and is recognized as a group 1 carcinogen by the Word Health Organization. The global rise in antibiotic resistance has increased clinical challenges in treating H. pylori infections. Biofilm growth has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Elshenawi, Yasmine, Hu, Shuai, Hathroubi, Skander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451559/
https://www.ncbi.nlm.nih.gov/pubmed/37627679
http://dx.doi.org/10.3390/antibiotics12081260
_version_ 1785095439047983104
author Elshenawi, Yasmine
Hu, Shuai
Hathroubi, Skander
author_facet Elshenawi, Yasmine
Hu, Shuai
Hathroubi, Skander
author_sort Elshenawi, Yasmine
collection PubMed
description Helicobacter pylori is a gastric pathogen that infects nearly half of the global population and is recognized as a group 1 carcinogen by the Word Health Organization. The global rise in antibiotic resistance has increased clinical challenges in treating H. pylori infections. Biofilm growth has been proposed to contribute to H. pylori’s chronic colonization of the host stomach, treatment failures, and the eventual development of gastric diseases. Several components of H. pylori have been identified to promote biofilm growth, and several of these may also facilitate antibiotic tolerance, including the extracellular matrix, outer membrane proteins, shifted morphology, modulated metabolism, efflux pumps, and virulence factors. Recent developments in therapeutic approaches targeting H. pylori biofilm have shown that synthetic compounds, such as small molecule drugs and plant-derived compounds, are effective at eradicating H. pylori biofilms. These combined topics highlight the necessity for biofilm-based research in H. pylori, to improve current H. pylori-targeted therapeutic approaches and alleviate relative public health burden. In this review we discuss recent discoveries that have decoded the life cycle of H. pylori biofilms and current biofilm-targeted treatment strategies.
format Online
Article
Text
id pubmed-10451559
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104515592023-08-26 Biofilm of Helicobacter pylori: Life Cycle, Features, and Treatment Options Elshenawi, Yasmine Hu, Shuai Hathroubi, Skander Antibiotics (Basel) Review Helicobacter pylori is a gastric pathogen that infects nearly half of the global population and is recognized as a group 1 carcinogen by the Word Health Organization. The global rise in antibiotic resistance has increased clinical challenges in treating H. pylori infections. Biofilm growth has been proposed to contribute to H. pylori’s chronic colonization of the host stomach, treatment failures, and the eventual development of gastric diseases. Several components of H. pylori have been identified to promote biofilm growth, and several of these may also facilitate antibiotic tolerance, including the extracellular matrix, outer membrane proteins, shifted morphology, modulated metabolism, efflux pumps, and virulence factors. Recent developments in therapeutic approaches targeting H. pylori biofilm have shown that synthetic compounds, such as small molecule drugs and plant-derived compounds, are effective at eradicating H. pylori biofilms. These combined topics highlight the necessity for biofilm-based research in H. pylori, to improve current H. pylori-targeted therapeutic approaches and alleviate relative public health burden. In this review we discuss recent discoveries that have decoded the life cycle of H. pylori biofilms and current biofilm-targeted treatment strategies. MDPI 2023-07-31 /pmc/articles/PMC10451559/ /pubmed/37627679 http://dx.doi.org/10.3390/antibiotics12081260 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Elshenawi, Yasmine
Hu, Shuai
Hathroubi, Skander
Biofilm of Helicobacter pylori: Life Cycle, Features, and Treatment Options
title Biofilm of Helicobacter pylori: Life Cycle, Features, and Treatment Options
title_full Biofilm of Helicobacter pylori: Life Cycle, Features, and Treatment Options
title_fullStr Biofilm of Helicobacter pylori: Life Cycle, Features, and Treatment Options
title_full_unstemmed Biofilm of Helicobacter pylori: Life Cycle, Features, and Treatment Options
title_short Biofilm of Helicobacter pylori: Life Cycle, Features, and Treatment Options
title_sort biofilm of helicobacter pylori: life cycle, features, and treatment options
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451559/
https://www.ncbi.nlm.nih.gov/pubmed/37627679
http://dx.doi.org/10.3390/antibiotics12081260
work_keys_str_mv AT elshenawiyasmine biofilmofhelicobacterpylorilifecyclefeaturesandtreatmentoptions
AT hushuai biofilmofhelicobacterpylorilifecyclefeaturesandtreatmentoptions
AT hathroubiskander biofilmofhelicobacterpylorilifecyclefeaturesandtreatmentoptions